First Glycoengineered, Humanized, Type II CD20 Monoclonal Antibody to Enter Clinical Trials Could Offer Hope for Difficu

Actualizado 08/12/2008 17:04:22 CET
Actualizado 08/12/2008 17:04:22 CET

First Glycoengineered, Humanized, Type II CD20 Monoclonal Antibody to Enter Clinical Trials Could Offer Hope for Difficu


For more information, please contact:
Peter Bayliss
Roche
Mobile: +41-7957-25193
Email: peter.bayliss@roche.com
Natalie Fairbank
Ketchum
Phone: +44-207-611-3660
Email: natalie.fairbank@ketchum.com

For more information, please contact: Peter Bayliss, Roche, Mobile: +41-7957-25193, Email: peter.bayliss@roche.com; Natalie Fairbank, Ketchum, Phone: +44-207-611-3660, Email: natalie.fairbank@ketchum.com

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación